E. M. Hersh
About
In The Last Decade
E. M. Hersh
158 papers receiving 4.1k citations
Peers
Comparison fields: 5 of 131
- Immunology 1.5k
- Oncology 1.5k
- Molecular Biology 1.1k
- Epidemiology 533
- Hematology 509
Countries citing papers authored by E. M. Hersh
This map shows the geographic impact of E. M. Hersh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. M. Hersh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. M. Hersh more than expected).
Fields of papers citing papers by E. M. Hersh
This network shows the impact of papers produced by E. M. Hersh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. M. Hersh. The network helps show where E. M. Hersh may publish in the future.
Co-authorship network of co-authors of E. M. Hersh
This figure shows the co-authorship network connecting the top 25 collaborators of E. M. Hersh. A scholar is included among the top collaborators of E. M. Hersh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. M. Hersh. E. M. Hersh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 90 | |
| 2 | 24 | |
| 3 | 83 | |
| 4 | 7 | |
| 5 | 5 | |
| 6 | 56 | |
| 7 | Tumor cytotoxicity of human peripheral blood monocytes activated by muramyl dipeptide analogues | 1 |
| 8 | Phase I study of MVE-2 therapy in human cancer | 2 |
| 9 | Some host defense modifying effects of intravenous microbial adjuvants | 1 |
| 10 | Response of L2C guinea pig leukemia to chemoimmunotherapy | 1 |
| 11 | Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without Bacillus Calmette-Guérin. | 9 |
| 12 | Systemic adjuvant therapy with BCG vs BCG + 5FU in colorectal cancer Dukes' class C: Updated analysis | 2 |
| 13 | Levamisole induced decline in lymphocyte content of cAMP among patients with solid tumors | 1 |
| 14 | An effective new chemoimmunotherapy regimen for disseminated malignant melanoma (DMM) | 9 |
| 15 | Chemoimmunotherapy of advanced non Hodgkin's lymphoma (NHL) with CHOP Bleo + levamisole | 5 |
| 16 | Immunostimulation with different BCG preparations during immunochemotherapy of melanoma | 3 |
| 17 | 61 | |
| 18 | Prolongation of post operative tumor free interval and survival in colorectal cancer by adjuvant BCG or BCG + 5 FU | 1 |
| 19 | Surface proteins of human acute myelogenous leukemia (AML) cells | 2 |
| 20 | Serial studies of immunocompetence in patients undergoing chemotherapy for acute leukemia | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.